Carina Antczak1, Vincent Q Trinh2, Akshay Sood3, Praful Ravi4, Florian Roghmann5, Vincent Trudeau2, Steven L Chang6, Pierre I Karakiewicz2, Adam S Kibel6, Nandita Krishna6, Paul L Nguyen7, Fred Saad8, Jesse D Sammon4, Shyam Sukumar9, Kevin C Zorn2, Maxine Sun2, Quoc-Dien Trinh6. 1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: carina.antczak@gmail.com. 2. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada. 3. Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan; Division of Urologic Surgery and Center for Surgery and Public Health, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 4. Vattikuti Urology Institute, Henry Ford Health System, Detroit, Michigan. 5. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, Ruhr University Bochum, Marienhospital, Herne, Germany. 6. Division of Urologic Surgery and Center for Surgery and Public Health, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 7. Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 8. Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. 9. Department of Urology, University of Minnesota, Minneapolis, Minnesota.
Abstract
PURPOSE: We examined temporal trends in skeletal related events and associated charges in patients with renal cell carcinoma metastatic to bone. We also identified patient and hospital characteristics associated with skeletal related events and related mortality. MATERIALS AND METHODS: Using the Nationwide Inpatient Sample we abstracted data on patients with renal cell carcinoma who were diagnosed with concomitant bone metastasis between 1998 and 2010. Patients who experienced a skeletal related event were identified and hospital charges were calculated. Multivariate regression models fitted with generalized estimating equations were used to examine predictors of skeletal related events and related in-hospital mortality. RESULTS: Between 1998 and 2010 a weighted estimate of 144,889 renal cell carcinoma hospital visits of patients with bone metastasis was identified in the Nationwide Inpatient Sample, of which 20.8% involved a skeletal related event. In these cases from 1998 to 2010 the inflation adjusted mean yearly costs associated with hospital admission increased by 207% in 2013 United States dollars (estimated annual percent change 8.94%, p<0.001). Conversely, the rates of skeletal related events and skeletal related event associated mortality decreased significantly (estimated annual percent change -1.11% and -2.9%, respectively, each p<0.001). CONCLUSIONS: The prevalence and in-hospital mortality of skeletal related event associated hospitalization for metastatic renal cell carcinoma is decreasing but such charges to health care in the United States are increasing at an alarming rate. These findings highlight the need for cost-effective treatment strategies to prevent or treat these morbid complications.
PURPOSE: We examined temporal trends in skeletal related events and associated charges in patients with renal cell carcinoma metastatic to bone. We also identified patient and hospital characteristics associated with skeletal related events and related mortality. MATERIALS AND METHODS: Using the Nationwide Inpatient Sample we abstracted data on patients with renal cell carcinoma who were diagnosed with concomitant bone metastasis between 1998 and 2010. Patients who experienced a skeletal related event were identified and hospital charges were calculated. Multivariate regression models fitted with generalized estimating equations were used to examine predictors of skeletal related events and related in-hospital mortality. RESULTS: Between 1998 and 2010 a weighted estimate of 144,889 renal cell carcinoma hospital visits of patients with bone metastasis was identified in the Nationwide Inpatient Sample, of which 20.8% involved a skeletal related event. In these cases from 1998 to 2010 the inflation adjusted mean yearly costs associated with hospital admission increased by 207% in 2013 United States dollars (estimated annual percent change 8.94%, p<0.001). Conversely, the rates of skeletal related events and skeletal related event associated mortality decreased significantly (estimated annual percent change -1.11% and -2.9%, respectively, each p<0.001). CONCLUSIONS: The prevalence and in-hospital mortality of skeletal related event associated hospitalization for metastatic renal cell carcinoma is decreasing but such charges to health care in the United States are increasing at an alarming rate. These findings highlight the need for cost-effective treatment strategies to prevent or treat these morbid complications.
Authors: Bernard Escudier; Thomas Powles; Robert J Motzer; Thomas Olencki; Osvaldo Arén Frontera; Stephane Oudard; Frederic Rolland; Piotr Tomczak; Daniel Castellano; Leonard J Appleman; Harry Drabkin; Daniel Vaena; Steven Milwee; Jillian Youkstetter; Julie C Lougheed; Sergio Bracarda; Toni K Choueiri Journal: J Clin Oncol Date: 2018-01-08 Impact factor: 44.544
Authors: Rana R McKay; Dominick Bossé; Kathryn P Gray; M Dror Michaelson; Katherine Krajewski; Heather A Jacene; Meghara Walsh; Joaquim Bellmunt; Mark Pomerantz; Lauren C Harshman; Toni K Choueiri Journal: Clin Cancer Res Date: 2018-05-30 Impact factor: 12.531
Authors: Kyrollis Attalla; Cihan Duzgol; Lily McLaughlin; Jessica Flynn; Irina Ostrovnaya; Paul Russo; Mark H Bilsky; A Ari Hakimi; Nelson S Moss Journal: Urol Oncol Date: 2021-01-07 Impact factor: 3.498